JP2015531376A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531376A5
JP2015531376A5 JP2015534652A JP2015534652A JP2015531376A5 JP 2015531376 A5 JP2015531376 A5 JP 2015531376A5 JP 2015534652 A JP2015534652 A JP 2015534652A JP 2015534652 A JP2015534652 A JP 2015534652A JP 2015531376 A5 JP2015531376 A5 JP 2015531376A5
Authority
JP
Japan
Prior art keywords
alkyl
ether
amine
aryl
thioether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531376A (ja
JP6480864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/061911 external-priority patent/WO2014052583A1/en
Publication of JP2015531376A publication Critical patent/JP2015531376A/ja
Publication of JP2015531376A5 publication Critical patent/JP2015531376A5/ja
Application granted granted Critical
Publication of JP6480864B2 publication Critical patent/JP6480864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015534652A 2012-09-27 2013-09-26 肥満の処置のための化合物およびそれの使用方法 Active JP6480864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
US61/706,153 2012-09-27
PCT/US2013/061911 WO2014052583A1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019021437A Division JP6743211B2 (ja) 2012-09-27 2019-02-08 肥満の処置のための化合物およびそれの使用方法

Publications (3)

Publication Number Publication Date
JP2015531376A JP2015531376A (ja) 2015-11-02
JP2015531376A5 true JP2015531376A5 (enExample) 2016-11-10
JP6480864B2 JP6480864B2 (ja) 2019-03-13

Family

ID=49304418

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015534652A Active JP6480864B2 (ja) 2012-09-27 2013-09-26 肥満の処置のための化合物およびそれの使用方法
JP2019021437A Active JP6743211B2 (ja) 2012-09-27 2019-02-08 肥満の処置のための化合物およびそれの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019021437A Active JP6743211B2 (ja) 2012-09-27 2019-02-08 肥満の処置のための化合物およびそれの使用方法

Country Status (21)

Country Link
US (6) US9968575B2 (enExample)
EP (3) EP4082541A1 (enExample)
JP (2) JP6480864B2 (enExample)
CN (3) CN111529535A (enExample)
AU (3) AU2013323528B2 (enExample)
BR (1) BR112015006848A2 (enExample)
CA (2) CA3030272C (enExample)
CY (1) CY1121166T1 (enExample)
DK (1) DK2900230T3 (enExample)
ES (1) ES2696626T3 (enExample)
HR (1) HRP20181879T1 (enExample)
HU (1) HUE040496T2 (enExample)
LT (1) LT2900230T (enExample)
PL (1) PL2900230T3 (enExample)
PT (1) PT2900230T (enExample)
RS (1) RS58010B1 (enExample)
RU (2) RU2650646C2 (enExample)
SI (1) SI2900230T1 (enExample)
SM (1) SMT201800604T1 (enExample)
TR (1) TR201815668T4 (enExample)
WO (1) WO2014052583A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111529535A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
BR112016021985B1 (pt) * 2014-03-26 2022-08-30 The General Hospital Corporation Formulação farmacêutica
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
CN119241632A (zh) * 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
EP4392044A4 (en) * 2021-09-09 2025-01-22 Junion Labs Pte. Ltd. SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
AU695934B2 (en) 1995-06-30 1998-08-27 Eli Lilly And Company Methods for treating diabetes
WO1997006816A1 (en) 1995-08-17 1997-02-27 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
CA2236163A1 (en) 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
WO1998008512A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
JP2001500869A (ja) 1996-09-20 2001-01-23 ヘキスト、アクチェンゲゼルシャフト 第ii種糖尿病におけるインスリン耐性を治療するためのレプチンアンタゴニストの使用
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
IL132380A0 (en) 1997-04-17 2001-03-19 Amgen Inc Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
CA2293504A1 (en) 1997-06-06 1998-12-10 Valur Emilsson Use of leptin antagonists for the treatment of diabetes
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
CA2337667C (en) 1998-08-10 2008-04-29 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1151102B1 (en) 1999-02-12 2006-04-19 Amgen Inc. Glycosylated leptin compositions and related methods
ATE475094T1 (de) 2001-10-22 2010-08-15 Amgen Inc Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
KR20050071605A (ko) 2002-10-21 2005-07-07 메타프로테오믹스, 엘엘씨 염증반응과 관련된 병리학적 상태를 치료하거나 저해하는조성물
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
WO2005069415A1 (ja) 2004-01-16 2005-07-28 Mitsubishi Materials Corporation 燃料電池用セパレータ、セパレータの製造方法および固体酸化物形燃料電池
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
RU2379037C2 (ru) 2005-09-30 2010-01-20 Моринага Милк Индастри Ко., Лтд. Средство для снижения резистентности к инсулину
CA2779041A1 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
EP2001897A2 (en) 2006-03-22 2008-12-17 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
JPWO2008020622A1 (ja) * 2006-08-17 2010-01-07 杏林製薬株式会社 新規なチエノ[2,3−d]ピリミジン化合物
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
EP2219664A1 (en) * 2007-11-14 2010-08-25 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
CN101434635B (zh) 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
CA2712593A1 (en) 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
US9132108B2 (en) 2009-04-17 2015-09-15 Hiroshima University Pharmaceutical composition for ameliorating and/or preventing leptin resistance, and use thereof
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
AU2011240690C1 (en) 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
CN101805390B (zh) 2010-04-13 2012-07-18 暨南大学 一种雷公藤红素衍生物及其用途
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
CA2808359C (en) 2010-08-23 2019-09-24 Suzhou Neupharma Co., Ltd. Analogs of celasterol and pharmaceutical compositions comprised thereof
WO2012036293A1 (ja) * 2010-09-17 2012-03-22 武田薬品工業株式会社 糖尿病治療剤
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
EA201492184A1 (ru) 2012-05-25 2015-07-30 Берг Ллк Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета
CN111529535A (zh) * 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Similar Documents

Publication Publication Date Title
JP2017513824A5 (enExample)
RU2016141567A (ru) Целастрол и его производные для лечения ожирения
AU2020203101B9 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
RU2018112067A (ru) Соединения, предназначенные для лечения ожирения, и способы их применения
RU2005123802A (ru) Производные адамантана, способы их получения и содержащие их фармацевтические композиции
KR20150013527A (ko) 항염증 활성과 접합된 증진된 항인플루엔자제
JP2013534248A5 (enExample)
RU2012128547A (ru) Дважды ацилированные производные glp-1
JP2018502101A5 (enExample)
RU2010116708A (ru) Бициклическое производное гамма-аминокислоты
RU2006142738A (ru) Антагонисты рецептора crth2
RU2013137452A (ru) Композиции, содержащие расщепляемое ферментами пролекарство оксикодона
WO2009082818A8 (en) Novel c-21-keto lupane derivatives preparation and use thereof
US20210137868A1 (en) Composition and methods for treating intestinal hyperpermeability
EP2682387A3 (en) C7-fluoro substituted tetracycline compounds
RU2012145116A (ru) Фармацевтическая композиция для предупреждения или лечения неалкогольного жирового гепатоза и способ предупреждения или лечения неалкогольного жирового гепатоза с ее использованием
JP2016537431A5 (enExample)
CA2446748A1 (en) Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
JP2009525265A5 (enExample)
JP2011526286A5 (enExample)
RU2012150501A (ru) Противораковые стероидные лактоны, ненасыщенные в положении 7(8)
CA2674550A1 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
WO2011085033A3 (en) Dp2 antagonist and uses thereof
RU2007128082A (ru) Новые производные циклогексана